7月 24, 2022
In 2020, Essilor introduced the Stellest™ lens, a new generation of spectacle lens solutions that slow the progression of myopia in children.
The first-year results of an ongoing clinical trial using the Stellest™ lens show more than 60% slowdown in myopia progression on average, when compared to children wearing single vision lenses.
As part of our ongoing efforts to combat this visual impairment, Essilor has also promoted white papers published by the International Myopia Institute (IMI). In October, Essilor announced a partnership with Myopia Profile, a global information platform, to develop educational content designed to help eye care professionals. The goal is to enhance their knowledge and skills for managing myopia in children more effectively.
SLOW DOWN MYOPIA PROGRESSION MORE THAN 60%
Myopia today represents a global health crisis, with five billion people, or half of the world’s population, expected to be myopic by 2050. It can progress rapidly in children, and may lead to sight-threatening eye diseases such as glaucoma, cataracts, retinal detachment and macular degeneration later in life. When detected early, myopia control solutions can help in slowing down its progression in children, reducing such risks and ensuring a better quality of life.
Myopia has been steadily increasing worldwide and in particular in China, with 54% prevalence in children aged 6-18 and 81% prevalence in children aged 18 years old1. As part of its mission to improve lives by improving sight and its commitment to focus resources where they are most needed, Essilor successfully launched Stellest™ lens in the Wenzhou Medical University Eye Hospital in China in July, with extremely positive feedback from parents and children alike. This will be continued with a broader roll-out in other hospitals in China, followed by several other countries.
The ongoing state-of-the-art three-year clinical trial on 167 myopic children2 started in 2018 in Essilor’s joint Research and Development Center with its key partner, the Wenzhou Medical University, in China. The one-year results already demonstrate strong evidence of the lenses’ effectiveness in slowing down myopia progression and promises to be Essilor’s best solution to fight myopia progression in children—in an aesthetic, efficient, safe, simple and easy to prescribe solution.
Key interim findings after one year revealed:
These promising interim findings were first unveiled at the World Society of Paediatric Ophthalmology and Strabismus (WSPOS) Worldwide Connect 2020 virtual congress, of which Essilor is a gold sponsor.
The Stellest™ lens has been designed with an exclusive and pioneering technology called “H.A.L.T.” technology (Highly Aspherical Lenslet Target) by Essilor’s industry-leading research and development teams. It is the culmination of more than 30 years of academic studies, product design, rigorous research efforts, and collaborating with the top research institutes and myopia experts.
SUPPORTS IMI EFFORTS ON MYOPIA MANAGEMENT
In a landmark moment for the eye care industry, the International Myopia Institute (IMI), a consensus body of global myopia experts with an independent advisory board, published a series of eight white papers last year. These white papers were sponsored by Essilor and other leading industry players, and provide a comprehensive, evidence-based picture of myopia management by some of the most respected minds in our field.
IMI has now released online the official IMI clinical summaries of the white papers in twelve languages including English, French, Chinese, Spanish, Vietnamese, Portuguese and Japanese, and many more languages as part of their commitment to make evidence-based knowledge free and accessible everywhere.
This ground-breaking effort has already seen important progress in advancing clinical knowledge and practice globally to help eye care professionals better assess and manage the growing epidemic among children.
Essilor International’s new partnership with Myopia Profile will see the development of specific educational content to increase primary eye care practitioners’ knowledge and skills in prescribing spectacle lenses to young children; getting started in myopia management; clinical communication and understanding the latest research. This content will include research summaries with clinical relevance, clinical case studies, podcasts and resources to use in practice. Content will be housed on MyopiaProfile.com and shared across the partnership’s multiple platforms.
Global myopia prevalence is rapidly growing, appearing to be driven primarily by environmental factors such as intensive education, less childhood time spent outdoors. Increased time spent on digital devices may also be a factor, although current findings on this relationship are mixed.
Myopia typically onsets in childhood and rapidly progresses, or worsens, until early adulthood. Higher levels of myopia are associated with higher lifelong risks of eye diseases such as cataract, retinal detachment and myopic maculopathy.
Childhood myopia progression cannot be stopped, but a growing body of research indicates that specific spectacle lenses, contact lenses and pharmacological interventions (eye medications) can slow down this progression. Altering a child’s visual environment to manage near-work time and increase time spent outdoors can also help. Reducing childhood myopia progression has the benefit of clearer vision with less changes, but even more so reduces lifelong risk of vision impairment due to myopia-associated eye diseases.
For more information on myopia in children, visit www.mykidsvision.org.